1. Technological in Nature
Activities must rely on principles of physical or biological sciences, engineering, or computer science.
The Research & Development (“R&D”) Tax Credit is one of the most valuable dollar-for-dollar tax incentives available under the Internal Revenue Code. Designed to encourage innovation and investment in the United States, the credit rewards businesses that design, develop, or improve products, software, or processes. Companies across a wide range of industries may qualify, often without realizing it.
The R&D Tax Credit allows eligible businesses to reduce their federal and state income tax liabilities by claiming credits for qualified research activities within the United States. Businesses may qualify for a credit of up to 10% on eligible expenses, including wages, supplies, cloud services, and contractor payments.
Many businesses are surprised to learn they qualify for R&D tax credits, even without operating in a traditional “lab” environment. In fact, many companies in software development, manufacturing, engineering, and other innovation-driven industries are eligible. Qualifying activities generally involve technical uncertainty and experimentation aimed at improving the functionality, performance, reliability, or quality of products, processes, or software.
In addition to offsetting federal income taxes, eligible businesses may use the R&D tax credit to offset the employer portion of payroll taxes (i.e., FICA/Medicare), allowing companies to benefit from the credit even if they are not yet profitable.
To qualify for the payroll tax offset, a company must meet the following criteria:
A formal R&D tax credit study typically evaluates projects against the IRS four-part test to determine eligibility. To qualify for the R&D Tax Credit, a project must meet all four of the following criteria:
R&D activities exist across many industries. The examples below highlight the various activities that many businesses perform daily that can qualify for the R&D tax credit.
Designing new products, prototypes, or models
Creating, testing, or enhancing software, including artificial intelligence and machine learning
Developing more efficient, automated, or environmentally friendly manufacturing processes
Creating technical designs, blueprints, and CAD models
Conducting feasibility studies, beta testing, and quality control on new or improved designs
Testing alternative materials to improve durability or performance
Withum provides comprehensive R&D tax credit services, supported by a dedicated team of R&D Tax Credit specialists serving companies across all industries. Our approach is designed to help businesses identify opportunities, maximize federal and state credits, and maintain taxing authority ready documentation to support, defend, and sustain credits year after year.
Withum offers a no obligation complimentary R&D tax credit assessment, beginning with a brief 30-minute discussion to determine your eligibility and estimate your potential credit benefit.
The life sciences industry is characterized by high-value intellectual property (“IP”), extensive research and development (R&D), complex regulatory environments, and global supply chains. Life sciences companies are increasingly global from day one where R&D is performed in one country, clinical trials in others, IP held centrally, and manufacturing and commercialization is performed elsewhere. These unique attributes create opportunity, but it also creates tax risk if global structuring and transfer pricing are not…
The R&D tax credit under IRC §41 is a statutory tax incentive, not a discretionary benefit, designed to reward companies for investing in innovation in the United States. While the opportunity can be significant, the credit is highly technical and documentation driven. At Withum, we believe the quality of an R&D tax credit study should…
A recent shift in federal policy materially changes how certain cannabis businesses should evaluate their Research and Development (R&D) Tax Credit position. On April 22, 2026, the Drug Enforcement Administration (DEA) issued a final order rescheduling specific cannabis products from Schedule I to Schedule III under the Controlled Substances Act. This change applies primarily to…
For more information or to discuss your business needs, please connect with a member of our team.